We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+26.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$849M
AUM Growth
+$158M
(+23%)
Cap. Flow
+$88.5M
Cap. Flow
% of AUM
10.43%
Top 10 Holdings %
Top 10 Hldgs %
48.96%
Holding
87
New
21
Increased
16
Reduced
27
Closed
18
Top Buys
| 1 |
ZBIO
Zenas BioPharma
ZBIO
|
+$25.5M |
| 2 |
Monte Rosa Therapeutics
GLUE
|
+$18.6M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$16.9M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$16.5M |
| 5 |
Immunome
IMNM
|
+$16.1M |
Top Sells
| 1 |
ABVX
Abivax
ABVX
|
+$14.2M |
| 2 |
CG Oncology
CGON
|
+$11M |
| 3 |
Viridian Therapeutics
VRDN
|
+$10.8M |
| 4 |
Pfizer
PFE
|
+$10.4M |
| 5 |
Avalo Therapeutics
AVTX
|
+$9.52M |
Sector Composition
| 1 | Healthcare | 98.55% |
| 2 | Financials | 1.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Spyre Therapeutics
SYRE
$8.59B
| $9.41M | 1.11% |
186,618
-1,119
| -0.6% | -$42.2K |
|
27
Biogen
BIIB
$28.3B
| $9.34M | 1.1% |
50,967
-24,445
| -32% | -$4.5M |
|
28
Guardant Health
GH
$21.2B
| $9.1M | 1.07% |
98,514
+6,600
| +7% | +$663K |
|
29
Vaxcyte
PCVX
$8.12B
| $8.42M | 0.99% |
144,981
-3,806
| -3% | -$207K |
|
30
Savara
SVRA
$1.17B
| $7.81M | 0.92% |
+1,430,982
| New | +$7.97M |
|
31
Benitec Biopharma
BNTC
$446M
| $7.64M | 0.9% |
717,725
-13,992
| -2% | -$162K |
|
|
ORKA
32
Oruka Therapeutics
ORKA
$5.28B
| $7.4M | 0.87% |
+150,908
| New | +$5.24M |
|
33
Compugen
CGEN
$218M
| $7.06M | 0.83% |
3,315,845
-163,960
| -5% | -$318K |
|
34
Trevi Therapeutics
TRVI
$2.54B
| $6.1M | 0.72% |
511,127
-30,113
| -6% | -$337K |
|
35
Insmed
INSM
$23.9B
| $5.86M | 0.69% |
35,850
-35,406
| -50% | -$5.44M |
|
36
Veracyte
VCYT
$4.52B
| $5.79M | 0.68% |
179,700
-177,858
| -50% | -$6.58M |
|
37
Cerus
CERS
$615M
| $5.78M | 0.68% |
3,176,547
+362,164
| +13% | +$789K |
|
38
Celldex Therapeutics
CLDX
$3B
| $5.66M | 0.67% |
178,378
-12,696
| -7% | -$346K |
|
39
C4 Therapeutics
CCCC
$421M
| $5.03M | 0.59% |
1,911,785
-82,439
| -4% | -$194K |
|
40
Cytokinetics
CYTK
$11.1B
| $4.69M | 0.55% |
+71,203
| New | +$4.53M |
|
|
CLYM
41
Climb Bio
CLYM
$758M
| $4.69M | 0.55% |
+684,908
| New | +$3.95M |
|
42
Compass Therapeutics
CMPX
$394M
| $4.54M | 0.54% |
859,049
-192,294
| -18% | -$1.11M |
|
43
Surrozen
SRZN
$254M
| $4.2M | 0.5% |
144,255
-13,068
| -8% | -$313K |
|
|
CTNM
44
Contineum Therapeutics
CTNM
$545M
| $3.94M | 0.46% |
301,729
-5,811
| -2% | -$77.9K |
|
45
Zura Bio
ZURA
$481M
| $3.34M | 0.39% |
+560,651
| New | +$3.39M |
|
46
Fulcrum Therapeutics
FULC
$239M
| $3.22M | 0.38% |
419,949
+25,299
| +6% | +$235K |
|
47
Abeona Therapeutics
ABEO
$402M
| $2.91M | 0.34% |
648,942
+21,204
| +3% | +$106K |
|
48
CAMP4 Therapeutics
CAMP
$231M
| $2.88M | 0.34% |
+653,594
| New | +$3.1M |
|
49
Annexon
ANNX
$909M
| $2.75M | 0.32% |
+496,461
| New | +$2.79M |
|
50
Elutia
ELUT
$40.3M
| $2.62M | 0.31% |
2,498,020
-253,294
| -9% | -$253K |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA